Browsing O - Articles científics by Title

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design

Agarwal, Neeraj; Azad, Arun; Shore, Neal; Fay, Andre P; Dunshee, Curtis; Carles, Joan (Future Medicine, 2022-02)

Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer

Garazi, Serna; Cecchi, Fabiola; Fasani, Roberta; Thyparambil, Sheeno; Elez Fernandez, Mª Elena; Vivancos Prellezo, Ana; Tabernero Caturla, Josep; Nuciforo, Paolo Giovanni; Landolfi, Stefania; Ruiz Pace, Fiorella; Jimenez, Jose; Dienstmann, Rodrigo (Nature Publishing Group, 2019-09-19)

Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies

Pesarrodona, Mireia; Jauset González, Antoni; Sánchez-Chardi, Alejandro; Seras Franzoso, Joaquin; Baltà Foix, Ricardo; Mancilla Zamora, Sandra; Fernández Amurgo, Yolanda; Schwartz Navarro, Simon; Abasolo Olaortua, Ibane; Diaz Riascos, Zamira Vanessa; Beaulieu, Marie-Eve; Soucek, Laura (Wiley Online Library, 2019-07-24)

Targeting DNA Damage Repair Mechanisms in Pancreas Cancer

Perkhofer, Lukas; Golan, Talia; Cuyle, Pieter-Jan; Matysiak-Budnik, Tamara; Van Laethem, Jean-Luc; Macarulla Mercadé, Teresa (MDPI, 2021-08-24)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

ADAM-ARTIGUES, ANNA; Brasó-Maristany, Fara; Cervera Vidal, Raimundo; Tormo, Eduardo; Arribas López, Joaquin Vicente; Arenas Lahuerta, Enrique Javier; Martínez-Sabadell, Alex (American Association for the Advancement of Science, 2022-05-20)

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models

Rodriguez, María Jimena; Perrone, María Cecilia; Riggio, Marina; Palafox Sánchez, Marta; Salinas, Valeria; Elia, Andres; Serra Elizalde, Violeta (Nature Portfolio, 2023-02-15)

Targeting MYC-driven lymphoma: lessons learned and future directions

Martínez Martín, Sandra; Beaulieu, Marie-Eve; Soucek, Laura (OAE Publishing, 2023-04-12)

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma

Geynisman, Daniel M.; Burotto, Mauricio; Suárez Rodríguez, Cristina; Bourlon, Maria T.; Huo, Stephen; Porta, Camillo (Springer, 2022-07)

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Sakai, Hiroshi; Felip Font, Enriqueta; Veillon, Remi; Garassino, Marina Chiara; Raskin, Jo; Le, Xiuning (American Association for Cancer Research, 2022-03-15)

Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial

Paik, Paul K.; Garassino, Marina; Le, Xiuning; Sakai, Hiroshi; Veillon, Remi; MAZIERES, JULIEN; FELIP, ENRIQUETA (American Medical Association, 2023-09-01)

TFIIIC as a Potential Epigenetic Modulator of Histone Acetylation in Human Stem Cells

Vezzoli, Marco; De Llobet Cucalon, Lara; Di Vona, Chiara; Morselli, Marco; Montanini, Barbara; de la Luna, Susana (MDPI, 2023-02-11)

TGFβ promotes widespread enhancer chromatin opening and operates on genomic regulatory domains

Guerrero-Martínez, Jose A.; Ceballos-Chávez, María; Koehler, Florian; Peiro Sales, Sandra; Reyes, Jose C. (Nature Research, 2020-12-03)

The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Jimenez-Fonseca, Paula; Foy, Victoria; Raby, Sophie; Macía Rivas, Lola; Arrazubi, Virginia; Mirallas Viñas, Oriol; Carmona-Bayonas, Alberto (SAGE Publications, 2023-03-04)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

Perez, Ariel; Iacoboni García-Calvo, Gloria; Penack, Olaf; Jentzsch, Liv; Carpio Segura, Cecilia Carmen; Barba Suñol, Pere; Rejeski, Kai; Bücklein, Veit (BMJ, 2022-05)

The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL

Wang, Yucai; albanyan, omar; Munoz, Javier; Rejeski, Kai; SESQUES, Pierre; IACOBONI, GLORIA; Barba, Pere (Wiley, 2023-11)

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates

Escriva de Romaní Muñoz, Santiago Ignacio; Saura Manich, Cristina (OAE Publishing, 2023-01-12)

The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways

Birrer, Michael J.; Fujiwara, Keiichi; Oaknin Benzaquen, Ana Mazaltob; Randall, Leslie; Ojalvo, Laureen S.; Valencia, Christian; Ray-Coquard, Isabelle (Frontiers Media, 2022-02-23)

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

Oza, Amit M.; Lorusso, Domenica; Aghajanian, Carol; Oaknin Benzaquen, Ana Mazaltob; Dean, Andrew; Colombo, Nicoletta (Elsevier, 2020-10-01)

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

Wardley, Andrew; Cortés Castan, Javier; Provencher, Louise; Miller, Kathy; Chien, A. Jo; Rugo, Hope (Springer, 2021-05)

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

Figlioli, Gisella; Bogliolo, Massimo; Catucci, Irene; Caleca, Laura; Lasheras, Sandra Viz; Pujol, Roser; Balmaña Gelpí, Judith; Diez Gibert, Orland (Nature Publishing Group, 2019-11-01)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Browsing VHIO - Articles científics by Title

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design

Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer

Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies

Targeting DNA Damage Repair Mechanisms in Pancreas Cancer

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models

Targeting MYC-driven lymphoma: lessons learned and future directions

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial

TFIIIC as a Potential Epigenetic Modulator of Histone Acetylation in Human Stem Cells

TGFβ promotes widespread enhancer chromatin opening and operates on genomic regulatory domains

The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates

The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

Know Scientia

Guides and help

Go to...

Know Scientia

Guides and help

Go to...

Browsing VHIO - Articles científics by Title

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design ﻿

Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer ﻿

Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies ﻿

Targeting DNA Damage Repair Mechanisms in Pancreas Cancer ﻿

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer ﻿

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models ﻿

Targeting MYC-driven lymphoma: lessons learned and future directions ﻿

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma ﻿

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice ﻿

Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial ﻿

TFIIIC as a Potential Epigenetic Modulator of Histone Acetylation in Human Stem Cells ﻿

TGFβ promotes widespread enhancer chromatin opening and operates on genomic regulatory domains ﻿

The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy ﻿

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL ﻿

The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL ﻿

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates ﻿

The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways ﻿

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma ﻿

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer ﻿

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer ﻿

Know Scientia

Guides and help

Go to...

Know Scientia

Guides and help

Go to...

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design

Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer

Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies

Targeting DNA Damage Repair Mechanisms in Pancreas Cancer

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models

Targeting MYC-driven lymphoma: lessons learned and future directions

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial

TFIIIC as a Potential Epigenetic Modulator of Histone Acetylation in Human Stem Cells

TGFβ promotes widespread enhancer chromatin opening and operates on genomic regulatory domains

The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates

The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer